

1 ***In silico* agent-based modeling approach to characterize multiple *in vitro* tuberculosis
2 infection models**

3 Alexa Petrucciani¹, Alexis Hoerter¹, Leigh Kotze², Nelita Du Plessis², Elsje Piennaar^{1,3*}

4

5 ¹Weldon School of Biomedical Engineering, Purdue University, West Lafayette, IN, USA

6 ²DSI-NRF Centre of Excellence for Biomedical Tuberculosis Research, South African Medical

7 Research Council for Tuberculosis Research, Division of Molecular Biology and Human

8 Genetics, Faculty of Medical and Health Sciences, Stellenbosch University, Cape Town, South

9 Africa.

10 ³Regenstrief Center for Healthcare Engineering, Purdue University, West Lafayette, IN, USA.

11

12 * Corresponding author

13 E-mail: epiennaar@purdue.edu (EP)

14

15

16

17

18

19

20

21

22

23

24

25

26

27 **Abstract**

28 *In vitro* models of *Mycobacterium tuberculosis* (*Mtb*) infection are a valuable tool to examine
29 host-pathogen interactions and screen drugs. With the development of more complex *in vitro*
30 models, there is a need for tools to help analyze and integrate data from these models. We
31 introduce an agent-based model (ABM) representation of the interactions between immune cells
32 and bacteria in an *in vitro* setting. This *in silico* model was used to independently simulate both
33 traditional and spheroid cell culture models by changing the movement rules and initial spatial
34 layout of the cells. These two setups were calibrated to published experimental data in a paired
35 manner, by using the same parameters in both simulations. Within the calibrated set,
36 heterogeneous outputs are seen for outputs of interest including bacterial count and T cell
37 infiltration into the macrophage core of the spheroid. The simulations are also able to predict
38 many outputs with high time resolution, including spatial structure. The structure of a single
39 spheroid can be followed across the time course of the simulation, allowing the relationship
40 between cell localization and immune activation to be explored. Uncertainty analyses are
41 performed for both model setups using latin hypercube sampling and partial rank correlation
42 coefficients to allow for easier comparison, which can provide insight into ideal use cases for the
43 independent setups. Future model iterations can be guided by the limitations of the current
44 model, specifically which parts of the output space were harder to reach. This ABM can be used
45 to represent more *in vitro* *Mtb* infection models due to its flexible structure, providing a powerful
46 analysis tool that can be used in tandem with experiments.

47

48 **Author Summary (150-200 words non tech)**

49 Tuberculosis is an infectious disease that causes over 1.4 million deaths every year. During
50 infection, immune cells surround the bacteria forming structures called granulomas in the lungs.
51 New laboratory models generate spheroids that aim to recreate these structures to help
52 understand infection and find new ways to treat tuberculosis. Computational modeling is used to

53 compare these newer spheroid models to traditional models, which don't recreate the structure
54 of the cell clusters. After calibration to data from laboratory experiments to ensure that the
55 computational model can represent both systems, the structures were characterized over time.
56 The traditional and spheroid model were also compared by looking at how model inputs impact
57 outputs, allowing users to figure out when one model should be used over the other. This
58 computational tool can be used to help integrate data from different laboratory models, generate
59 hypothesis to be tested in laboratory models, and predict pathways to be targeted by drugs.

60

61 1. Introduction

62 Tuberculosis (TB) continues to be a global public health crisis, responsible for 1.4 million
63 deaths in 2021 alone.(1) TB is caused by the bacteria *Mycobacterium tuberculosis* (*Mtb*).
64 Generally, *Mtb* is introduced to its host upon inhalation of contaminated respiratory droplets,
65 allowing direct entry into the lungs. Bacteria are deposited in the well-ventilated lower lobes of
66 the lung, where alveolar macrophages phagocytose them.(2) *Mtb* is subsequently able to
67 survive and replicate within the endosomes of these macrophages.(3) As the infection
68 progresses, infected macrophages release chemokines and cytokines which recruit other
69 immune cells (e.g. monocytes, T cells, B cells, NK cells, dendritic cells, and neutrophils) to form
70 a granuloma. A granuloma is generally comprised of a core of infected macrophages,
71 surrounded by monocytes, epithelioid macrophages, foamy macrophages, neutrophils,
72 multinucleated giant cells, and finally a lymphocytic cuff with an outer fibrous capsule.(4) The
73 timing and spatial organization of key host-pathogen interactions within these granuloma
74 structures, and how these interactions contribute to bacterial survival or elimination, remains
75 incompletely understood. This is in part due to the complexity of the granuloma structure itself,
76 which makes it difficult to understand, measure, and/or predict host-pathogen interactions and
77 their impact on infection progression.

78 Many systems have been used to explore granulomas in TB; each having its own
79 benefits and limitations. While much has been revealed about the structure of granulomas from
80 work in humans, clinical studies are invasive or indirect and are often lacking in time points
81 required to evaluate granuloma dynamics. Additionally, TB granulomas in humans can only
82 really be studied at later stages when the infection has been established and diagnosed.(5)
83 Animal studies such as non-human primate (NHP), rabbit, and mouse models are very useful
84 and allow more control and direct observation of infection and granuloma formation than in
85 humans. Mouse models benefit from wide availability of commercial immunological reagents,
86 genetic tools, and transgenic and knock-out strains, but most mouse strains struggle to recreate
87 the structure of granulomas seen in humans.(6,7) Rabbit and guinea pigs are able to form
88 necrotic and non-necrotic mature granulomas. (6,7) These models have been limited in the past
89 by availability of immunological reagents, but recently more commercially available
90 immunological reagents like antibodies against rabbit analytes have been developed.(6–9) NHP
91 models most closely recreate human pathology, with heterogenous clinical outcomes and
92 granuloma structures.(10,11) But NHP models are expensive, time-intensive, and limited by the
93 availability of animal facilities.(6,7) It is difficult to do certain genetic manipulations, collect data
94 at many time points, and control the exact cellular and environmental makeup of the system in
95 these *in vivo* models. Complementary to these *in vivo* models, there has been recent work
96 developing more complex *in vitro* cellular cultures to both dissect biological mechanisms and
97 test new therapies (reviewed in Elkington et al.(12)). *In vitro* models can be particularly helpful
98 because the system is tractable, and all cellular components of the system can be controlled. *In vitro*
99 models are also cheaper and higher throughput than the equivalent *in vivo* models. *In vitro*
100 systems can be mechanistically perturbed and dynamically sampled in ways that are extremely
101 difficult in *in vivo* models.

102 Elkington et al. suggest certain criteria for an ideal *in vitro* model including the use of
103 human cells and virulent *Mtb*; allowing incorporation of fibroblast, epithelial cells, and

104 physiological extracellular matrix; being modular to allow many different biological questions to
105 be answered; and, ideally, being 3-dimensional (3D).(12) However, increasing complexity isn't
106 necessary in all cases and can make models lower-throughput and more expensive. Ideally, *in*
107 *vitro* models could be tailored to the biological question at hand, but still be able to be compared
108 across platforms. *In vitro* models could then be optimized to include only the necessary
109 components, allowing maintenance of inexpensive, high-throughput models. Results from many
110 disparate systems could still be synthesized to form robust conclusions.

111 We recently developed an *in vitro* biomimetic 3D spheroid granuloma model.(13) Briefly,
112 patient-derived alveolar macrophages are infected with BCG, and magnetic nanospheres used
113 to levitate the cells. Autologous adaptive immune cells isolated from peripheral blood
114 mononuclear cells (PBMCs) were added at 48 hours into the 6 day culture. When comparing
115 this granuloma model to a corresponding traditional monolayer culture, we found the spheroid
116 model was better able to control bacteria. Differences in bacterial count between these models
117 can be quantified and are due to the different model setups, but how the spatial aspects impact
118 immune response is unclear. These two systems provide a good test case to evaluate the
119 possibility of translating between different *in vitro* systems, and identify the key mechanisms at
120 work in the different systems.

121 This data not only motivates a need to understand the mechanistic differences between
122 these two models, but also highlights a need to more broadly look at the complexity and
123 spatiality of *in vitro* models. As we move towards more complex *in vitro* models, organoids,
124 complex cell mixtures etc., it is important that we 1) understand and quantify the impact of the
125 structural organization of the cultures, and 2) develop tools that are able to analyze these more
126 complex systems, and 3) develop tools that can enable us to compare and translate between
127 systems. Computational models are well-suited to address all of these tasks.

128 Computational models are inexpensive compared to *in vitro* or *in vivo* models, quick to
129 run, highly manipulatable, able to integrate data from many sources, and can easily be adapted

130 to reflect new data.(12,14) Beyond this, computational models can be used to perform
131 perturbations (e.g. virtual knockouts) that would be extremely difficult in a wet lab setting.
132 Computational models work especially well in combination with *in vitro* work, where hypotheses
133 can be generated computationally and tested experimentally in an iterative fashion.(12)
134 Mechanistic models specifically use individual interactions between cells and molecules to
135 predict emergent tissue-level outcomes (e.g. granuloma dynamics). Because individual cellular
136 and molecular interactions are based on current biological understanding, we can use the
137 emergent behavior of our simulations to test hypotheses about the driving mechanisms for
138 tissue-level outcomes. Beyond hypothesis testing, mechanistic models also act to integrate
139 existing knowledge into a single framework to help understand their collective impact. One type
140 of mechanistic model, agent-based models (ABMs), are stochastic spatiotemporal models that
141 are particularly suited to look at emergent spatial behavior. Stochasticity is ideal because it
142 captures some of the heterogenous host response to TB.(15,16) Spatiality is required as we aim
143 to represent and contrast both traditional and 3D models.

144 Mechanistic modeling has been applied to TB since 1962, and ABMs in particular have
145 been used in the context of TB since 2004.(17–19) ABMs of granuloma formation in the non-
146 human primate (NHP) lung have been iterated many times to look at the impacts of TNF- α (20–
147 22), *Mtb* metabolism(23), macrophage (M Φ) polarization(24), and more(25–30). In this work, we
148 apply these established agent-based approaches to *in vitro* systems. This means that all
149 components included in the experimental system can be accounted for, the experimental
150 system can be more easily observed and perturbed, and we can use one simulation framework
151 with different initializations to represent, and translate between, many *in vitro* models. In this
152 work we use one computational agent-based modeling framework to recreate the results from
153 both 3D spheroid and the corresponding traditional culture *in vitro* models(13). Our
154 computational model generates high time-resolution data for cellular outputs, along with spatial
155 data. This spatial data is processed in multiple ways, allowing us to dissect the evolution of a

156 single granuloma and explore the heterogeneity of the host response within different spatial
157 organizations. Finally, we use uncertainty analysis to look at the similarities and differences
158 between the spheroid and traditional setups.

159

160 **2. Methods**

161

162 **2.1. Experimental Methods**

163

164 The data we use for calibration is derived from a biomimetic 3D spheroid model of a granuloma
165 and the corresponding traditional culture. Briefly, HIV negative patients with high suspicion of
166 TB were recruited. Bronchoscopies were performed by qualified clinicians and nursing staff
167 according to international guidelines (31) to obtain bronchoalveolar lavage fluid samples.

168 Immediately after bronchoscopy, peripheral blood was collected by venipuncture into two 9mL
169 sodium heparinized (NaHep) vacutainers. Alveolar macrophages were isolated from

170 bronchoalveolar fluid, and PBMCs were isolated from peripheral blood using the Ficoll-Paque
171 isolation method described previously (13). Alveolar macrophages were cultured at a density of
172 4×10^5 cells per well in a 24-well low-adherence culture plate and infected with *Mycobacterium*
173 *bovis* Bacille Calmette-Guerin (BCG) at a multiplicity of infection (MOI) of 1 for 4 hours.

174 Afterwards, extracellular bacteria were removed by supplementing media with an antimycotic
175 antibiotic (penicillin/streptomycin/amphotericin B) for 1 hour, followed by successive washes.

176 The 3D spheroids were made by treating alveolar macrophages with biocompatible NanoShuttle
177 (n3D Biosciences Inc., Greiner Bio-One) and levitating them using the magnetic levitating drive.

178 After 48 hours, 6×10^5 autologous CD3+ T cells are added per well. The traditional culture is
179 made using the same cells and the same ratios, but without NanoShuttle treatment and
180 subsequent magnetic levitation.


181 Granuloma structures were mechanically disrupted by gentle pipetting after 6 days of
182 culture. Cell count and cell viability were determined using the trypan blue exclusion method
183 after adherent cells were removed. CFU counts were determined by lysing mechanically
184 disrupted cells and plating serial dilutions on Middlebrook 7H11 agar plates (BD Biosciences).
185 After 21 days of growth, the colonies were manually counted. 3D spheroids were also fixed,
186 embedded in tissue-freezing medium OCT (Tissue-Tek; USA), and cryosectioned. A section
187 from the middle of the structure was stained with antibodies for CD3+ and CD206+ cells and
188 imaged using a Carl Zeiss LSM 880 Airyscan with Fast Airyscan Module confocal microscope
189 (Plan-Apochromat x63/1.40 oil DIC UV-VIS-IR M27 lens objective). The image of the traditional
190 cell culture was acquired with light microscopy at 40x magnification. For full methods please
191 reference Kotze et al. 2021.

192

193 **2.2. Model Structure**

194 Our model simulates the interactions between macrophages, CD4+ T cells, CD8+ T cells,
195 bacteria, and two simplified cytokines within an *in vitro* environment. The simulation is
196 constructed as a hybrid multiscale model with a cellular level agent-based model hybridized to a
197 partial differential equation model of diffusion for the two cytokines (TNF α -like and IFN γ -like).
198 These will be referred to as TNF α and IFN γ moving forward. The environment is composed of
199 grid cubes that each represent a 20 μ m x 20 μ m x 20 μ m volume, which is the approximate size of
200 our largest agent type, the macrophage.(32) The environment has two overlying grids, one
201 single occupancy grid for immune cells and one multioccupancy for the smaller bacteria. The
202 simulation has 4 types of agents: macrophages, CD4+ T cells, CD8+ T cells, and bacteria.
203 Macrophages can be subdivided into uninfected and infected classes. Agent behaviors are
204 performed with a time step of 6 minutes, the approximate time for a monocyte to move 20 μ m,
205 or one grid cube. (33–36) The simulation is run for a total of 6 days, to reflect the duration of the

206 *in vitro* experiments. An overview of agent behaviors is shown in Figure 1 and further detail is
207 given below. These methods are in part drawn from work modeling NHP granulomas *in silico*,
208 specifically GranSim and subsequent developments.(18,19)
209
210



211
212
213 **Figure 1:** An overview of rules for the simulated agents. a) Bacteria grow and divide. b) Immune
214 cells secrete cytokines dependent on activation or infectious state, move probabilistically up a
215 TNF- α gradient, age, and die. c) Macrophages (M Φ) can phagocytose bacteria becoming
216 infected. d) M Φ activation is represented by a two-step process. NF- κ B can be activated by
217 TNF- α , bacteria, or direct contact with an activated CD4+ T cell. STAT1 is activated by IFN- γ
218 secreted by activated T cells. e) Infected M Φ either fight infection killing internal bacteria and

219 returning to uninfected state, or when a certain threshold of bacteria is reached will burst
220 releasing internal bacteria into the environment. f) TB-Specific CD4+ T cells activate by
221 interacting with a MΦ that has interacted with a bacterium. After activation, CD4+ T cells can
222 proliferate. g) TB-Specific CD8+ T cells activate by interacting with a MΦ that has interacted
223 with a bacterium and is STAT1 activated. After activation, CD8+ T cells can proliferate and kill
224 infected macrophages along with the internal bacteria. Created with BioRender.com.

225 **2.2.1. Diffusing molecules**

226 There are 2 diffusing molecules included representing the simplified TNF- α and IFN- γ . These
227 are contributed to by the secreting agents, and diffuse in the simulation space. Diffusion is
228 performed similarly to that in Weathered et al. using a 3D alternating-direction explicit numerical
229 method.(37) As this method is unconditionally numerically stable, a larger dt than is predicted by
230 the conditional stability criterion can be used while maintaining accuracy.(38) After finding dt
231 suggested by the conditional stability criterion and the diffusion parameters a multiplier of 4 was
232 incorporated into the alternating-direction explicit method to reduce simulation time, while
233 maintaining accuracy, as recommended by Cilfone et al.(38) The PDE is run with a smaller time
234 step than the ABM, ranging from 2 to 14 diffusion iterations per agent time step depending on
235 the diffusion parameters. IFN- γ and TNF- α are diffused separately with separate diffusion
236 coefficients and decay rates. The rate of diffusion is slowed within granulomas by
237 *granulomaFractionOfDiffusion*.

238

239 **2.2.2. Agents**

240 **Immune cells**

241 Macrophages, infected macrophages, CD4+ and CD8+ T cells are all classified as types of
242 immune cells. This parent class of agents share common behaviors, including movement and
243 aging. Movement is determined by gravity limited or 3D rules. Cells moving in 3D are able to

244 move in any direction. With gravity limited rules, cells will fall in the z dimension if no immune
245 cell is below them and can only move up in the z direction if on top of another immune cell.
246 Given these movement rules, the cells will chemotax probabilistically toward the highest
247 concentration of TNF- α when the summed TNF- α in the Moore neighborhood is above
248 *TNFthresholdForImmuneCellMovement*. This chemotaxis algorithm is based off of that in
249 Weathered et al..(37) Immune cells also age according to individualized lifespans. A resting
250 lifespan and activated lifespan are selected for each cell from a *populationLifespan* * (1+/-
251 *lifeSpanVariance*). These lifespans are then converted to aging rates, which change according
252 to the activation status of the cell. The resting aging rate is 1 hour aged per hour, while the
253 activated aging rate is calculated as resting lifespan divided by activated lifespan. At
254 initialization a cell will be given a random starting age from zero to the resting lifespan. Then a
255 cell's current age gets incremented by the aging rate each time step. When a cell reaches its
256 maximum age, it will die and be removed from the simulation.

257

258 **Macrophages**

259 Beyond the immune cell rules described above, macrophages will attempt to phagocytose and
260 activate every time step. Each macrophage attempts to phagocytose by picking a bacterium in
261 its Moore neighborhood at random. If this bacterium is extracellular, it will be phagocytosed with
262 a phagocytosis probability dependent on activation state (*basePhagocytosisProbability*,
263 *activePhagocytosisProbability*). Successful phagocytosis turns a macrophage into an infected
264 macrophage. Macrophages that have phagocytosed bacteria also get classified as having
265 interacted with bacteria, meaning antigenic peptides can be displayed on the cell surface. Each
266 macrophage also checks for activation. Activation is represented by a simplified two step
267 signaling process, requiring STAT1 and NF- κ B activation.(39) Each of these two pathways can
268 be activated, if they are not already activated. STAT1 is activated if local IFN- γ is greater than
269 *IFNthresholdForStat1Activation*. NF- κ B can be activated in 3 ways: TNF- α greater than

270 *TNFthresholdForNFkBActivation*, nearby extracellular bacteria greater than
271 *bacThresholdForNFkBActivation*, or direct interaction with an activated CD4+ T cell. These
272 represent TNF- α interaction with TNFR, activation of TLR, and CD40-CD40L interactions,
273 respectively.(40) All three of these NF- κ B activation methods will be checked in a random order.
274 NF- κ B and STAT1 activations last for set durations after the signal was initially received
275 (*nfkbSpan* and *stat1Span*). These durations have variances, *nfkbVariance* and *stat1Variance*, to
276 introduce heterogeneity into the population. After the macrophage-specific length of activated
277 time, the pathway will deactivate and be checked again immediately, to allow longer activation if
278 the activation signals persist. If both pathways are activated at the same time, then the
279 macrophage becomes fully activated. Activation changes a macrophage's movement
280 probability, phagocytosis probability, and aging rate. Activated macrophages also secrete TNF- α
281 at a rate of *ActivatedMacrophageTNFSecretion* molecules per second.

282

283 **Infected Macrophages**

284 Infected macrophages can fight the infection at each time step. An internal bacterium is selected
285 randomly and will be killed with a probability that is dependent on the macrophage's activation
286 state (*baseKillingProbability*, *activeKillingProbability*). If all the bacteria within an infected
287 macrophage are killed, then the infected macrophage reverts to a healthy macrophage. Infected
288 macrophages can be activated through the same pathways as healthy macrophages. When
289 fully activated, the phagocytosis and killing probabilities change to values for activated
290 macrophages. Infected macrophages secrete TNF- α when activated, but also constitutively
291 secrete TNF- α at a baseline level of *InfectedMacrophageTNFSecretion* molecules per second
292 when not activated. Infected macrophages don't move but can continue to phagocytose bacteria
293 if the number of internalized bacteria is below *phagocytosisThreshold*. This occurs similarly to
294 the initial phagocytosis, with a random bacterium selected from the infected macrophage's
295 Moore neighborhood that will be taken up with some probability if it is extracellular. Once the

296 number of internal bacteria is above *cellularDysfunctionThreshold* the macrophage is
297 considered chronically infected.(19) Chronically infected macrophages can no longer be fully
298 activated or kill internal bacteria. If the number of bacteria within an infected macrophage
299 reaches a bursting threshold the macrophage will burst and release the internal bacteria into the
300 environment. This threshold has been experimentally determined to be 20-40 internal bacteria in
301 *in vitro* systems.(41) A burst limit was randomly selected for each infected macrophage from a
302 uniform distribution from 20 to 40 internal bacterial. When a macrophage dies of old age the
303 bacteria are similarly released into the environment.

304

305 **CD4+ T cells**

306 CD4+ cells can be TB specific or non-TB specific. TB specific CD4+ T cells can also become
307 activated. Activation of TB specific CD4+ T cells occurs with a probability of
308 *CD4ActivationProbability* if a random macrophage in its Moore neighborhood has interacted
309 with bacteria. This is equivalent to antigen presentation on MHC II. (40) Activation increases
310 movement probability and aging rate. Activated CD4+ T cells secrete both TNF- α at
311 *ActivatedCD4TNFSecretion* molecules per second and IFN- γ at *ActivatedCD4IFNSecretion*
312 molecules per second.(42) Active CD4+ T cells can also divide with a doubling time of
313 *cd4PopulationDoublingTime* until the maximum number of generations
314 (*maximumCD4Generations*) is reached. Individual variance is introduced to doubling time.
315 Deactivation occurs with a given probability *CD4DeactivationProbability* per time step.

316

317 **CD8+ T cells**

318 Just like CD4+ T cells, CD8+ T cells can be subdivided into TB specific and non-TB specific. TB
319 specific CD8+ T cells can be activated. If a randomly selected macrophage within the T cell's
320 Moore neighborhood is STAT1 activated and has interacted with bacteria, then the T cell will
321 probabilistically activate (*CD8ActivationProbability*). STAT1 activation is a proxy for interaction

322 between CD4+ T cell and macrophage which increases expression of molecules on the surface
323 of the APC(B7 and 4-1BBL) that provide co-stimulation to naïve CD8+ T cells.(40,43) If
324 activated, a CD8+ T cell will secrete both TNF- α (*ActivatedCD8TNFSecretion*) and IFN- γ
325 (*ActivatedCD8IFNSecretion*). Activation also increases movement probability and aging rate.
326 Activated CD8+ T cells will also divide with a doubling time of *cd8Population_DoublingTime* until
327 the maximum generation (*maximumCD8Generations*) is reached. Activated CD8+ T cells have
328 the ability to kill infected macrophages (equivalent to cells presenting peptides in MHC I). A
329 random infected macrophage is selected for the Moore neighborhood, and the infected
330 macrophage and all internal bacteria are killed with a probability *CD8KillProbability*. CD8+ T
331 cells deactivate probabilistically (*CD8DeactivationProbability*).
332

333 **Bacteria**

334 Bacteria grow and divide. Bacteria have biomass that gets added to every tick. The rate of
335 growth depends on whether they are intracellular or extracellular. Growth rate is calculated from
336 doubling time (*mtbInternalDoublingTime*, *mtbExternalDoublingTime*), and includes some
337 individual variance from the population mean. If the biomass threshold of 2 is reached, then the
338 bacteria divide into two with the biomass distributed among them unevenly(44). Simulated
339 bacteria represent BCG, as BCG was used in the *in vitro* models. Behaviors/parameters draw
340 from both BCG and TB literature.
341

342 2.2.3. Initial Conditions

343 The differences between the spheroid and traditional simulations include the movement rules
344 and the initial spatial distribution of cells. Our initial conditions reflect those used in the *in vitro*
345 system.(13)
346

347 **Spheroid**

348 In the experimental protocols, 400,000 macrophages are infected with MOI 1 and then
349 levitated.(13) At day 2, 600,000 CD3+ cells are added in a dropwise manner directly to the
350 spheroid. Due to computational limitations associated with the 3D simulation of a full-sized
351 spheroid, we simulate a spheroid of 1/10th the size. We generate a sphere of 40,000 mixed
352 healthy and infected macrophages. Given the experimental MOI of 1, we use a Poisson
353 distribution to estimate percentage of cells with various number of phagocytosed bacteria(45).

354 The fraction of macrophages that have phagocytosed n bacteria is given by $\frac{MOI^n e^{-MOI}}{n!}$.

355 Macrophages with zero to six internalized bacteria are initialized, giving 39,997 initial bacteria.
356 This sphere is centered on an 80x80x80 grid representing 1.6 mm x 1.6 mm x 1.6 mm volume.

357 The radius of the initialized sphere is calculated as $\sqrt[3]{\frac{cellCount * 3}{4 \pi sphereEfficiency}}$, with the initial density of
358 the cells determined by *sphereEfficiency*. At day 2, 60,000 CD4+ and CD8+ T cells are added in
359 a cuff around the macrophages. Proportions of CD4+ T cells (*fractionCD4*), CD8+ T cells
360 (*CD8Fraction*), and TB specific T cells (*fractionTBSpecific*, *tbSpecificCD8Fraction*) are
361 estimated from literature. (46–49) Subsets of the immune cells are allowed to be preactivated
362 (*activatedMacrophageProportion*, *activatedTBSpecificCD4Fraction*,
363 *activatedTBSpecificCD8Fraction*) as the alveolar macrophages and PBMCs were taken from
364 patients with active TB. Activated TB specific T cells are given a random starting generation and
365 starting point in the division cycle as the process of proliferation could have already started.

366

367 **Traditional culture**

368 The experimental conditions are the same as the spheroid without the inclusion of the magnetic
369 levitation beads. As with the spheroid, a simulation 1/10th the size of the experiment. This is
370 simulated by adding 40,000 infected and uninfected macrophages distributed evenly through
371 the environment. After these macrophages are added they fall to the bottom of the plate due to
372 the gravity-limited movement discussed in section 2.2.2.1. Since the cells would all be at the

373 bottom of the plate, the dimensions were adjusted to 216x216x11, or 4.32mmx4.32mmx0.22
374 mm. The ratio of cells to the surface area of the plate is kept constant between the experimental
375 system and the simulation. Additionally, the volume of simulation, and therefore initial cellular
376 density, is minimally different between the spheroid and traditional models. The percentage of
377 cells with various number of phagocytosed bacteria is calculated in the same manner as the
378 spheroid model. On day 2, 60,000 CD4+ and CD8+ T cells are distributed evenly throughout the
379 environment before falling.

380

381 **2.2.4. Simulation**

382 This model is built using Repast Simphony 2.8, an open source software used to build ABMs in
383 Java.(50) Simulations were run on the Purdue Brown Cluster and on XSEDE resources.(51)
384 Python and MATLAB were used for data analysis and visualization.

385

386 **2.3. Calibration**

387 Calibration is performed by doing an initial parameter sweep and then iterating around specific
388 parameter sets. These iterations are used to find a variety of parameter sets that fit into the
389 experimental data range while iterating into harder to reach parts of the output space.

390 Experimental data ranges used for calibration include:

391 • Spheroid bacterial fold change from 4 hpi to day 6
392 • Traditional bacterial fold change from 4 hpi to day 6
393 • Spheroid cell viability at day 6
394 • Traditional cell viability at day 6
395 • Spheroid cell count at day 6
396 • Traditional cell count at day 6

397 A total of 50 parameters are varied in the model (Table 1). Initial ranges are determined from
398 relevant literature (*in silico*, *in vivo*, *in vitro*) or left broad. Latin hypercube sampling (LHS) was
399 used to sample 1,000 parameter sets from initial ranges with a centered design (Table 1).
400 These parameter sets are run in both the traditional and spheroid simulation with 7 replicates as
401 a broad initial sweep. Top runs are defined as those with the highest traditional CFU, as this
402 part of the output space had few runs in the initial sweep. The top five runs that met the
403 bacterial fold changes for traditional and spheroid are iterated. Iterations are performed by
404 narrowing the parameter range to 20% of the initial range centered around the initial point (each
405 of the top five runs). One hundred samples in this new range are generated using LHS and are
406 run in triplicate. The number of replicates and runs are reduced due to computational costs.
407 Runs that passed all 6 criteria (bacterial fold changes, cell viability, and cell count at day 6 for
408 traditional and spheroid cultures) are iterated until there was less than a 10% increase in
409 traditional culture CFU. The iterating range is then narrowed to 10% of the initial range, and
410 iterated until again there is a less than 10% increase in traditional culture CFU. The calibrated
411 set is generated by selecting runs that fits all 6 criteria from all of the simulations. Thus, our
412 approach allows us to enrich areas that fell within experimental ranges while directing the
413 traditional CFU higher in order to fill out the whole experimental range.

414 **Table 1:** Parameters that are varied during calibration. Initial ranges are either determined by
415 literature, estimated through preliminary simulations (e), or broadened to the full mathematically
416 possible range (f). The set of calibrated parameter sets can be found in the provided data.

Parameter	Initial Range	Units	Refs
Bacteria			
<i>mtbInternalDoublingTime</i>	23,69	Hours	(53)
<i>mtbExternalDoublingTime</i>	23,69	Hours	(53)
Macrophages			

<i>activatedMacrophageProportion</i>	0,0.1	Per tick	e
<i>baseKillingProbability</i>	0.0001,0.02	Per tick	e
<i>activeKillingProbability</i>	0.002,0.3	Per tick	e
<i>basePhagocytosisProbability</i>	0,1	Per tick	f
<i>activePhagocytosisProbability</i>	0,1	Per tick	f
<i>phagocytosisThreshold</i>	8,12	Internal bacteria	(22)
<i>cellularDysfunctionThreshold</i>	8,12	Internal bacteria	(22)
<i>nfkbSpan</i>	0.16,166	Hours	(24)
<i>TNFthresholdForNFkBActivation</i>	40,500	Molecules	e
<i>bacThresholdForNFkBActivation</i>	20,150	External bacteria	(22)
<i>stat1Span</i>	0.16,166	Hours	(24)
<i>IFNthresholdForStat1Activation</i>	40,500	Molecules	e
<i>ActivatedMacrophageTNFSecretion</i>	0,40	Molecules/second	(42)
<i>InfectedMacrophageTNFSecretion</i>	0,40	Molecules/second	(42)
<i>macrophagePopulation_MaxLifespan</i>	20,100	Days	(22)
<i>macrophagePopulation_MaxActivatedLifeSpan</i>	7,13	Days	(22)
<i>baseMovementProbabilityMacro</i>	0.5,1	Per tick	(33–36)
<i>activatedMovementProbabilityMacro</i>	0,0.5	Per tick	e
CD4+ T cells			
<i>fractionCD4</i>	0.5,0.65	CD4+ T cells/ CD3+ T cells	(46,47)

<i>fractionTBSpecific</i>	0.0001,0.06	TB specific CD4+ T cells/ Total CD4+ T cells	(48,49)
<i>activatedTBSpecificCD4Fraction</i>	0,0,1	Initial activated TB specific CD4 T cells/ Total TB specific CD4 T cells	e
<i>CD4ActivationProbability</i>	0,1	Per tick	f
<i>CD4DeactivationProbability</i>	0,1	Per tick	f
<i>ActivatedCD4TNFSecretion</i>	0,40	Molecules/second	(42)
<i>ActivatedCD4IFNSecretion</i>	0,40	Molecules/second	(42)
<i>cd4PopulationDoublingTime</i>	6,16	Hours	(54,55)
<i>maximumCD4Generations</i>	3,10	Generations	(54,56 ,57)
<i>cd4Population_MaxLifespan</i>	34,340	Days	(58– 60)
<i>cd8Population_MaxLifespan</i>			
<i>cd4Population_ActivatedLifespan</i>	2.5,4	Days	(22,54)
<i>cd8Population_MaxActivatedLifespan</i>			
<i>baseMovementProbabilityCD4</i>	0,1	Per tick	f
<i>baseMovementProbabilityCD8</i>			
<i>activatedMovementProbabilityCD4</i>	0,1	Per tick	f
<i>activatedMovementProbabilityCD8</i>			
CD8+ T cells			
<i>CD8Fraction</i>	0.3,0.35	CD8+ T cells/ CD3+ T cells	(46)

<i>tbSpecificCD8Fraction</i>	0.0001,0.06	TB specific CD8+ T cells/ Total CD8+ T cells	(48,49)
<i>activatedTBSpecificCD8Fraction</i>	0,0.1	Initial activated TB specific CD8 T cells/ Total TB specific CD8 T cells	e
<i>CD8ActivationProbability</i>	0,1	Per tick	f
<i>CD8DeactivationProbability</i>	0,1	Per tick	f
<i>ActivatedCD8TNFSecretion</i>	0,40	Molecules/second	(42)
<i>ActivatedCD8IFNSecretion</i>	0,40	Molecules/second	(42)
<i>cd8PopulationDoublingTime</i>	3,13	Hours	(55)
<i>maximumCD8Generations</i>	7,20	Generations	(56,57 ,61)
<i>CD8KillProbability</i>	0.012,0.12	Per tick	(22)
Diffusion			
<i>TNFthresholdForImmuneCellMovement</i>	1,500	Molecules	e
<i>TNFDiffusionCoefficient</i>	0.1,1	$10^{-7} \text{ cm}^2/\text{s}$	(24)
<i>TNFDegradationRatePerSecond</i>	0.96,10	1/s	e
<i>IFNDiffusionCoefficient</i>	0.1,1	$10^{-7} \text{ cm}^2/\text{s}$	(24)
<i>IFNDegradationRatePerSecond</i>	0.96,10	1/s	e
<i>granulomaFractionOfDiffusion</i>	0,1	-	f
<i>sphereEfficiency</i>	0.65,0.9	-	e

417

418

2.4. Uncertainty analysis

419 LHS and partial rank correlation coefficients (LHS-PRCC) are used to perform an uncertainty
420 analysis.(52) LHS-PRCC has been used in similar systems to characterize monotonic
421 relationships between inputs and outputs.(52) One thousand samples are selected from the
422 initial range using LHS and run with 7 replicates. These replicates are averaged before PRCCs
423 are calculated at day 2 before the T cells are added and day 6. A significance level of 0.01 is
424 used with a Bonferroni correction for the number of tests run. The relationship between the 50
425 varied parameters and 9 outputs of interest (totalMtbCount, mtbKilledByActivatedMacCount,
426 mtbKilledByRestingMacCount, mtbKilledByCD8Count, activatedCD4Count, totalActivatedCD8s,
427 activatedMacroCount, totalStat1MacroCount, totalNfkbMacroCount) are analyzed.

428


429 **2.5. Matching Unpaired Runs**

430 To be able to explore output spaces that are not accessible using the paired simulations
431 described above, we also analyze matched simulations. Unpaired spheroid and traditional
432 simulations are matched by selecting runs with similar (but not identical) initial condition
433 parameters: *CD8Fraction*, *fractionCD4*, *fractionTBSpecific*, and *tbSpecificCD8Fraction*. To
434 identify matched simulations, the spheroid runs are looped through for each traditional run, and
435 a cost function was calculated. This function sums squared errors divided by maximum value for
436 these 4 controlled parameters (*CD8Fraction*, *fractionCD4*, *fractionTBSpecific*, and
437 *tbSpecificCD8Fraction*). The spheroid run with the lowest cost is selected to be matched to the
438 unpaired traditional run.

439

440 **3. Results**

441



442

443 **Figure 2:** Paired simulations are calibrated to data from *in vitro* cultures. Spheroid and
444 traditional simulations are run with the same parameters, only varying the initial spatial layout of
445 cells and the movement rules. Comparison of experimental data to calibrated simulation data for
446 a) CFU fold change from 4 hpi to 6 days, b) cell viability at day 6, and c) cell count at day 6. d)
447 Bacterial count dynamics for calibrated spheroid and traditional simulations over the 6 day time
448 course show heterogeneous behaviors. Spheroid and traditional simulations are visualized at
449 day 6 for comparison to *in vitro* images. f) A slice of the *in vitro* spheroid culture on day 6.
450 (Adapted with permission from Kotze et al. 2021) g) A slice through the center of a spheroid
451 simulation. h) Full spheroid simulation. i) A brightfield image of the *in vitro* traditional culture on
452 (day 6). j) Traditional simulation viewed top down. k) Traditional simulation viewed from side. ***
453 $p \leq 1e-3$

454 **3.1. Results from multiple systems can be reproduced with one *in silico*
455 framework.**

456 We first test whether or not the multiscale model can recreate the experimental data for
457 bacterial fold change, cell count, and cell viability at day 6. Using the calibration method
458 described above, parameter sets are identified whose output fit criteria for both spheroid and
459 traditional data. (Figure 2a-c) These simulations give CFU fold change outputs that span most
460 of the experimental range, except for the highest experimentally measured CFUs in the
461 traditional cultures. Together this suggests we are able to recreate experimental data from
462 multiple *in vitro* systems using the same sets of parameters (Appendix Figure 1) and the same
463 model structure.

464 After calibrating to both experimental systems, representative calibrated runs are
465 visualized to compare with experimental images as a qualitative validation. Simulated spheroids
466 (Fig. 2g,h) qualitatively match experimental microscopy (Fig. 2f), having a layered structure with
467 macrophages on the inside and T cells in a cuff around the edge. The whole spheroid is situated

468 in the middle of the simulated space with a very dense center with some cells less densely
469 around the outside. The layered structure of the spheroid can be contrasted with the more well-
470 mixed and dense traditional simulation (Fig. 2j,k) and experiments (Fig. 2i). These cells are
471 localized at the bottom of the simulation space, due to the gravity-limiting spatial rules. These
472 visualizations also highlight the versatility of the computational model, allowing the same base
473 set of rules to recreate multiple *in vitro* culture systems. In summary, this quantitative calibration
474 and qualitative validation indicates that our simulation-predicted spatial organization aligns well
475 with experimental data.

476 Beyond recreating existing experimental data, our computational model can also predict
477 high time resolution outcomes. Bacterial time courses show the heterogeneity of behaviors
478 possible given both the initial conditions and the experimental range at day 6. (Fig 2d) This
479 heterogeneity can give us insight into potential system dynamics and generate new testable
480 hypotheses. Predictions can then be tested by designing experiments to distinguish among
481 predicted behaviors by identifying time points and outputs of interest with the simulation. For
482 example, macrophage activation (Fig 2e) could be compared with M1 activation markers *in vitro*
483 at day 2.5 to differentiate between the two groups of spheroid simulations with different
484 predicted timings of macrophage activation.

485 Taken together, these results indicate that that our computational framework can
486 reproduce both bulk and spatial data from multiple experimental systems. Additionally, high
487 time- and space-resolution predictions can be made about cell counts and interactions.

488


489

490

491

492

493



494

495 **Figure 3:** a) The spatial development of a single granuloma over 6 days. The radial distribution
496 of b) macrophages, CD4+ T cells, and CD8+ T cells; c) base and activated T cells; d) NF- κ B
497 and STAT1 activated macrophages; e) base and activated macrophages.


498 **3.2. Our computational framework predicts high time resolution spatial data,
499 including the evolution of a single spheroid over time.**

500 In *in vitro* and *in vivo* experiments, a granuloma must be destroyed to produce IHC or
501 other data, meaning each time point corresponds to a different granuloma. In contrast, *in silico*
502 models allow us to look at the evolution of spatial phenomenon *in situ*, meaning a single
503 granuloma can be followed from creation to the end of the experiment.

504 These spatial dynamics can be analyzed both visually and quantitatively. Visually, an
505 initial sphere of mixed infected and uninfected macrophages is seen at day 1 with a cuff of T

506 cells being added at day 2 (Fig 3a). Macrophage activation starts at the interface of the
507 macrophages and T cells and moves towards the center as time progresses. This activation
508 corresponds to some T cell infiltration into the macrophage core. In this specific run, more CD8+
509 T cell activation leads to more infiltration by this population. Quantitatively, we can look at the
510 radial density of cells and cell subpopulations to see similar trends (Fig 3b-e). Radial density
511 graphs were generated by calculating the distances of the cells to the center of the spheroid,
512 generating a histogram for the cells of interest by dividing them into preset bins, and then
513 normalizing by the total volume in each bin which corresponds to the volume of a spherical
514 shell. The simulation starts with uniformly distributed macrophages, before a cuff of uniformly
515 distributed CD4+ and CD8+ T cells is added (Fig 3b). As time progresses the T cells spread out
516 and begin to infiltrate the macrophage core, especially CD8+ T cells in this representative
517 simulation. In our simulation, these T cells only contribute to the immune response when they
518 are activated, so T cells are subdivided into resting and activated (Fig 3c). Activated T cells are
519 more localized towards the center of the granuloma. This makes sense as interacting with a
520 macrophage presenting antigenic peptides is required for T cell activation, and bacteria and
521 macrophages that have interacted with bacteria are going to be localized to the core. These
522 activated T cells provide one of the signals required for macrophage activation, STAT1 via IFN-
523 γ . The distribution of this signal can be overlaid with the other required signal, NF- κ B, giving
524 insight into how macrophage activation propagates from the outside in (Fig 3d). The distribution
525 of fully activated macrophages (Fig 3e) closely follow the STAT1 signal, suggesting in this
526 model T cells are the limiting step of activation. The widespread NF- κ B activation suggests it is
527 not the limiting step, especially as macrophages are NF- κ B activated from day 1 forward. This is
528 likely due to TNF- α secretion from the intermixed infected macrophages.

529 Taken together, this illustrates how we can use our models to quantify key host-
530 pathogen interactions in space and time in a single granuloma.



531

532 **Figure 4:** Example simulations with a) extensive and b) limited T cell infiltration into the
533 macrophage core. A slice through the center of the granuloma is shown at day 6. c) Mean and
534 standard deviation radial density of macrophages and T cells. Runs are sorted by mean T cell
535 distance minus one standard deviation.

536 **3.3. A distribution of outcomes, including T cell infiltration, is seen among
537 spheroid simulations.**

538 Given that T cell signaling is important for macrophage activation, T cell infiltration
539 becomes an output of interest. Visually, we noted the variation in T cell infiltration of the
540 spheroids between parameter sets (Fig. 4a,b). Calibrated runs can show almost no infiltration
541 (Fig. 4a) to almost homogeneous mixing of macrophages and T cells (Fig. 4b). To evaluate the
542 heterogeneity across all of our simulations, the mean and standard deviation of radial density is
543 calculated for macrophages and T cells for each simulation. This gives a mean position when
544 correcting for the uneven volumes of the radial spheres. These measures for T cells and
545 macrophages range from having nearly complete overlap to almost complete separation (Fig
546 4c). Over half of the simulations have macrophages with means around 10. However, many
547 simulations also have higher macrophage means closer to the T cell means, suggesting more

548 intermixing between T cells and macrophages among these runs. Little infiltration was seen in
549 the *in vitro* model at day 6,(13) which aligns with some but not all of our simulated runs. Either
550 the small sample size of the experimental study doesn't account for full heterogeneity or this
551 information can be used to further narrow the parameter space moving forward.


552 One way to look at the infiltration of T cells is to look at the difference between the T cell
553 mean and macrophage mean. The higher the value the more separation between the cell types
554 and, therefore, more structure. Spearman's rank correlation coefficients were calculated
555 between this distance measure of separation and outputs of interest at day 6 with $\alpha = 0.01$. Our
556 model suggests this measure of separation is not significantly correlated to total bacterial count
557 ($p = 0.091292$, $p = 0.068859$). However, this model is only looking at runs that were calibrated
558 to experimental data, which has a small range of bacterial count for the spheroid simulations. If
559 increasing T cell separation was an isolated change it's possible that this relationship would be
560 seen.

561 Although the bacterial counts in the spheroid simulations are all within a small range, the
562 bacterial counts in the corresponding traditional simulations vary more. The Spearman's rank
563 correlation coefficient between our separation measure and the traditional total bacterial count
564 shows a significant positive correlation ($p = 0.561759$, $p < 0.000001$). The parameter sets that
565 show more separation in the spheroid have higher bacterial load in the traditional cultures. So,
566 this would suggest that those parameter sets rely on a lot of structure to be able to control
567 bacteria, because when those parameters are used to simulate the traditional well-mixed
568 conditions, the bacteria are not as well controlled. On the other hand, those parameter sets that
569 don't have a lot of separation, do equally well in controlling bacteria in both the spheroid and
570 traditional. Parameter sets with less separation resemble the traditional organization, so similar
571 results are expected. So, bimodal results are seen, where there's two different ways that the
572 model can control the bacteria – one is structure dependent and the other is not.

573 Other correlations seen between separation measure and outputs of the spheroid model
574 include *activatedMacroCount* ($p = 0.307164$, $p < 0.000001$), *activatedInfectedMacroCount* ($p =$
575 0.419979 , $p < 0.000001$), *totalStat1MacroCount* ($p = 0.307557$, $p < 0.000001$), and
576 *totalActivatedCD8s* ($p = 0.171726$, $p = 0.000580$). Increasing separation correlates to more
577 STAT1 and total macrophage activation, including activation of the infected macrophage
578 population. CD8+ T cell activation is also positively correlated with separation. Due to the
579 distribution of separation, we are able to look at the impact of spatial layout of cells on many
580 outputs.

581 Taken together, these results illustrate that our simulations can produce a wide range of
582 outcomes that are consistent with the experimental data; and how these simulations can be
583 used to explore how granuloma structure impacts bacterial control and activation.

584



585

586 **Figure 5:** Impact of input parameters on simulation outputs at day 2 before the T cells are
 587 added and day 6. Correlation coefficients for spheroid and traditional simulations are shown in
 588 the same heatmap with the traditional in the lower left hand corner and the spheroid in the upper
 589 right. Insignificant correlations are shown in white, while positive and negative correlation are
 590 shown with red and blue, respectively. Significance was determined with $\alpha = 0.01$ and a
 591 Bonferroni correction.

592 **3.4. Comparisons between the models using uncertainty analysis can help identify**
593 **ideal use cases.**

594 LHS-PRCC is performed on the initial large LHS sweep to quantify how uncertainty in
595 the parameters impacts uncertainty in the outputs of both the spheroid and traditional
596 simulations. At day 2 before the T cells have been added to the simulation, the spheroid and
597 traditional simulations show similar responses to changes in parameters. Total bacterial count is
598 inversely correlated with the doubling time of the internalized bacteria and the killing ability of
599 the resting macrophages. All of the bacteria at the beginning of the simulation are internal due
600 to a washing step after the infection of the macrophages. Lower doubling times of these bacteria
601 lead to more generations and more bacteria. Poorer killing ability of the resting macrophages
602 leads to more bacteria.

603 Before the addition of T cells, resting macrophages are responsible for all of the
604 bacterial killing. Cytotoxic CD8+ T cells have yet to be added to the culture, and T cells are
605 required to fully activate macrophages. So, *mtbKilledByRestingMacCount* accounts for all of the
606 killing and closely aligns with the *totalBacterialCount*. Base killing probability is positively
607 correlated with *mtbKillingByRestingMacCount*, as better killing ability leads to more killed
608 bacteria.

609 Total NF- κ B activated macrophages is the only other output showing significant
610 correlations with parameters before day 2. NF- κ B signal can come from TNF- α or bacteria and
611 is required for total activation. Total NF- κ B activated macrophages are correlated to *nfkbSpan*,
612 *baseKillingProbability*, *InfectedMacrophageTNFSecretion*, and
613 *macrophagePopulation_MaxLifespan*. *nfkbSpan* is the length of time that NF- κ B stays active
614 after receiving the initial signal, so the longer this time period is the more NF- κ B activated
615 macrophages there are. When *baseKillingProbability* is lower, fewer bacteria are killed, and
616 more bacteria and infected macrophages are available to activate NF- κ B. Higher TNF- α

617 secretion from infected macrophages also leads to more activation. Lastly, longer macrophage
618 lifespans mean more macrophages are alive to be activated.

619 After the T cells are added, the total bacteria count is more dependent on CD4+ T cell
620 parameters. The internal doubling time and base killing probability are both still negatively
621 correlated with total bacteria count. The rest of the significantly correlated parameters are
622 associated with CD4+ T cells and STAT1 activation. Fewer TB specific CD4+ T cells, less CD4+
623 T cell activation, and more CD4+ deactivation all reduce the amount of activated CD4+ T cells
624 indirectly leading to more bacteria. Higher threshold for STAT1 activation by IFN- γ , higher
625 degradation rate for IFN- γ , and less CD4+ T cell IFN- γ secretion all lead to less macrophage
626 STAT1 activation. Again, this will indirectly lead to more bacteria. With the inclusion of adaptive
627 immune cells, the responses of the two set ups also diverge more. For bacterial counts the only
628 difference is due to external bacteria. Lower external doubling time leads to more bacteria only
629 in the traditional simulation, as the population of external bacteria is so small in the spheroid
630 simulation.

631 Macrophage activation is mostly dependent on CD4+ T cell parameters in both models.
632 However, increased macrophage activation in the traditional simulation is also correlated with
633 increased macrophage lifespans and decreased CD4+ T cell doubling time. This suggests that
634 macrophage death might be limiting the population size in traditional runs. Also, a higher CD4+
635 T cell population will lead to more macrophage activation.

636 CD8+ T cell activation is correlated with parameters related to CD4+ T cells, CD8+ T
637 cells, and IFN- γ . Differences between the two models include negative correlations between the
638 probability of deactivation/population doubling time and total CD8+ T cell activation. Less
639 deactivation or more proliferation should lead to higher activated populations.

640 The only parameter-output relationship seen just in the spheroid simulation is a positive
641 correlation between the *baseKillingProbability* and total NF- κ B activated macrophages. This is
642 the opposite of the relationship seen at day 2. One hypothesis for this relationship is that more

643 killing initially leads to less macrophage activation and subsequent death. This is supported by
644 positive correlations between macrophage lifespans and this output.

645 Despite these differences, the two models have many similar responses to changing
646 parameters. For example, the total activated CD4+ T cells show the same relationships for both
647 the spheroid and traditional simulations with regards to all parameters. The significantly
648 correlated parameters are all related to CD4+ T cells: fraction of TB specific cells, activation
649 probability, deactivation probability, and doubling time.

650 Altogether, these results show that similar parameters are driving dynamics in the
651 spheroid and traditional models before day 2, but the influential parameters diverge after the
652 addition of T cells. These correlations can be used to select what *in vitro* model is needed when
653 designing experiments, as main drivers of outputs can be identified. For example, the traditional
654 simulation has a correlation between macrophage lifespans and macrophage activation that is
655 not seen in the spheroid. This relationship suggests that macrophage lifespans influence
656 macrophage activation in the traditional culture, so a spheroid might be more appropriate if the
657 biological question under investigation relates to drivers of macrophage activation.

658



659

660 **Figure 6:** a) Traditional simulations that fell above the paired range and matched spheroid
661 simulations. b) Significantly different parameters between the set of high traditional simulations
662 and matched spheroid simulations.

663 **3.5. Limitations in representing both systems can guide future model iterations.**

664 The analysis done thus far is based on paired calibration. Pairing the simulations makes
665 the assumption that everything except for the initialization and movement is the same between
666 the spheroid and traditional simulations. While this assumption allows us to recreate a majority
667 of the experimental range, the highest traditional CFU counts are unable to be recreated with
668 paired runs. Traditional runs with high levels of bacteria falling in this range are seen, but the
669 corresponding spheroid simulation did not meet calibration criteria. This suggests that in order
670 to reproduce these high traditional CFU results, some parameters (i.e. biological mechanisms)
671 may need to be different between the spheroid and traditional simulations. To investigate this
672 possibility, we evaluate unpaired simulations that are allowed to have different parameter values
673 between traditional and spheroid simulations, but that are matched as closely as possible for
674 initial conditions that are expected to be the same.

675 Traditional runs are matched with spheroid runs that meet calibration criteria and have
676 similar initial conditions as defined in the methods. After these runs are matched, the
677 parameters of the spheroid and traditional simulations are compared. Nine parameters are
678 found to be significantly different (Figure 6). Some of these parameter differences can lead to
679 less bacteria in the spheroid directly or indirectly by increasing activation. The matched spheroid
680 runs had higher internal doubling time of the bacteria meaning the bacteria grow more slowly
681 and a higher resting macrophage killing rate leading to more bacterial killing. Therefore, the
682 matched spheroid runs have less bacteria than the traditional runs directly due to less growth
683 and more killing. The matched spheroid runs also have parameter differences that lead to more
684 macrophage activation. Lower *IFNthresholdForStat1Activation* in spheroid runs would give more
685 STAT1 activation of macrophages causing more overall macrophage activation. Lower
686 *CD4DeactivationProbability* in spheroid runs would prolong CD4+ T cell activation giving these
687 cells more opportunities to activate macrophages. Lastly, lower

688 *TNFDegradationRatePerSecond* in spheroid runs maintains higher concentrations of TNF- α ,
689 leading to more NF- κ B activation of macrophages.

690 The role of the other parameters is less clear. Lower *activatedTBSpecificCD4Fraction*,
691 lower *ActivatedCD8TNFSecretion*, and higher *TNFthresholdForNFkBActivation* would all
692 suggest lower macrophage activation in the spheroid. Lower *baseMovementProbabilityCD4*
693 could delay activation of TB specific T cells or could lead to less spatial interference by non-TB
694 specific T cells in spheroids. As these simulations are matched after the fact, some of these
695 differences are potentially spurious. However, these differences can guide future computational
696 and experimental studies by highlighting hypothesized functional differences between traditional
697 and spheroid cultures.

698

699 **4. Discussion**

700 *In silico* models have been used previously to represent multiple *in vitro* systems for other
701 diseases. In 2006, Grant et al. used cellular automata to represent the growth of epithelial cells
702 in 4 conditions: 3D embedded, suspension, surface, and collagen overlay cultures.(62) They
703 were able to recreate the complex structure associated with each condition with a set of axioms
704 governing the interactions of cells, matrix, and cell-free space. The difference between a 2D and
705 3D culture system has also been modeled to explore viral dynamics and drug toxicity. A network
706 model of tumor cell infection by oncolytic viruses was simulated in a 2D monolayer and 3D
707 environment.(63) This model suggested that traditional mean field models overestimate how
708 effective therapy would be. Beyond this, infection in a 3D environment was shown to have a
709 smaller chance of tumor eradication, emphasizing the need for ideal virus characteristics: fast
710 replication and slow tumor cell killing. A virtual cell based assay was extended from 2D cultures
711 to 3D spheroids to predict drug toxicity.(64) This model was found to represent 3D *in vitro*
712 models well, which show higher drug toxicity than 2D monolayers.

713 In all instances, space is explicitly modeled to gain insight into the system behavior in
714 different configurations. The spatial configurations alter dynamics of the system and can change
715 important predictive outcomes, such as drug response. Similar to these prior works, we explicitly
716 include space to model two different environmental setups. We show that spatial organization
717 alone can change the dynamics of the system and primary outcome, bacterial count. Moving
718 forward, we can use our simulations to predict which model outcomes are likely to be affected
719 by spatial organization and therefore guide experimental decisions.

720 Note, we are using a single *in silico* framework to represent separate traditional and 3D
721 cell cultures. A separate problem, representing one *in vivo* or *in vitro* system with both a 2D and
722 3D computational model, has also been addressed.(65,66) Models of *in vivo* granulomas and *in*
723 *vitro* spheroids suggest that 2D representations of 3D systems (i.e. slice through center of
724 structure) have similar results and save computational time.(65,66)

725 Granulomas are spatial organized structures, with a core of macrophages and a cuff
726 including CD4+ and CD8+ T cells.(67) The center of the granuloma is a more pro-inflammatory
727 environment, while the cuff has more anti-inflammatory cytokines.(68,69) Higher frequencies of
728 pro-inflammatory cytokines or lymphocytes are correlated with lower bacterial burden, but it is
729 suggested that a balance of pro- and anti-inflammation is necessary to limit both bacterial
730 growth and pathology.(69–71) While we don't explicitly include anti-inflammatory pathways in
731 this preliminary model, our model does show pro-inflammatory signals localized to the core.
732 Specifically, macrophage activation is limited by the interactions between IFN- γ and
733 macrophages which begins at the periphery of the core and moves inwards. This looks similar
734 to the pattern of p-STAT1 seen in peripheral regions in immunohistochemistry of NHP
735 granulomas.(72) Previous computational modeling also suggests the importance of IFN- γ
736 producing T cells and interactions between macrophages and T cells for bacterial control.(73) It
737 emphasizes the importance of spatial organization as interactions between CD11c+

738 macrophages and T cells are limited due to the cellular distributions within granulomas and the
739 recruitment of non-specific T cells.

740 While the structure of our model is artificially constructed rather than emerging from
741 immune interactions, the similar spatial patterns for cells and activation is encouraging. Further
742 comparison could be accomplished by applying our methods for analyzing the distribution of cell
743 types and signals within granulomas to *in vitro* and *in vivo* data in the future.

744 The evolution of a single granuloma can be followed over time in other systems. Sequential
745 imaging with [18F] fluorodeoxyglucose positron emission tomography and computed
746 tomography has been used to follow disease progression in NHP and track response to TB
747 treatment in humans.(74–76) This imaging gives information at the lesion-tissue scale.

748 Fluorescent *in vivo* microscopy of zebrafish embryos has given insight into the cellular level
749 dynamics.(77) Imaging after infection of zebrafish embryos with *Mycobacterium marinum* allows
750 tracking of infected macrophages providing information about early granuloma formation and
751 dissemination. Recently, a method to study zebrafish granulomas *ex vivo* called Myco-GEM was
752 created that allows continuous lightsheet imaging for upwards of 8 hours.(78) With tagging of
753 cytokines, specific cells, or bacteria the inflammatory state of the granuloma, granuloma
754 dynamics, cell movement, and bacterial load can be longitudinally examined.

755 Our model similarly provides dynamic information at the cellular scale. Beyond this, we can
756 gather information about bulk cell counts, cell activation status, and cytokine concentrations
757 without perturbing the observed system. Thus, our computational model can complement *in*
758 *vitro* experimental systems, by providing both high-resolution spatiotemporal information and
759 bulk information about host-pathogen interactions within individual granuloma structures.

760 Simulations with virtual perturbations on knockouts can then quickly be run to examine how
761 these interactions contribute to bacterial survival or elimination.

762 TB is a very heterogenous disease. There are many different clinical outcomes: bacterial
763 clearance, asymptomatic latent infection, and active infection.(71,79) These host level outcomes

764 are dependent on a population of granulomas, which can be very heterogenous even within the
765 same lung.(76,80) Granulomas have many different structures which can lead to bacterial
766 dissemination, control, or clearance.(71,79) Our *in vitro* models are more controlled with an
767 established structure and proportion of cell types. Smaller sample numbers still showed a large
768 range of bacterial control, which can be recreated *in silico*. We also see heterogeneity in T cell
769 localization *in silico*. While this is not seen as much *in vitro*, there is some variability *in vivo*.
770 Early granulomas have T cells dispersed throughout, while well-developed ones are more
771 structured with a ring of T cells.(81) Being able to reproduce a diversity of granuloma
772 organizations will allow us to explore how different microenvironments contribute to granuloma
773 trajectory and treatment response.

774 LHS-PRCC has been used to look at correlations between inputs and outputs in simulations
775 of *in vivo* NHP granulomas. While our time points don't line up with the longer *in vivo*
776 simulations, we can compare parameter influences before and after adaptive immunity has
777 been added. In the first iteration of the NHP granuloma simulation, there are similarities to our
778 model.(19) This model from literature shows a strong positive correlation between intracellular
779 growth rate and total extracellular bacteria during early infection.(19) As infection progresses
780 extracellular bacteria in the simulated NHP granulomas becomes negatively correlated with T
781 cell parameters, namely recruitment, movement, and activation of macrophages.(19)

782 In these simulations of *in vivo* granulomas all bacteria start extracellularly, while all bacteria
783 start intracellularly in our *in vitro* model. Our primary output of interest then becomes
784 intracellular bacteria, which shows a similar relationship with the intracellular growth rate before
785 the addition of the adaptive immune system. Some comparisons between this *in vivo* simulation
786 and our *in vitro* simulation are limited because *in vivo* mechanisms are missing *in vitro*, like
787 cellular recruitment. But we see an increased importance of T cell parameters on our output of
788 interest after adaptive immunity is initiated as in this literature model. In our short term
789 'artificially' assembled spheroids, we see similar parameter influences to *in vivo* granulomas.

790 Therefore, some comparisons can be made not only between our two *in vitro* models, but also
791 *in vivo* simulations, to be able to rationally identify good use cases for various *in vitro* systems.

792 Our model is not without limitations. The only PBMC derived CD3+ T cells simulated are
793 CD4+ and CD8+ T cells. Some subsets of T cells (e.g. regulatory and $\gamma\delta$) are excluded from the
794 model for the purpose of simplification. Simplifications are also made to the macrophage
795 activation pathway. The model only incorporates M1 macrophage polarization/activation
796 represented as a 2-step pathway, and M2 macrophage polarization is not included.

797 Additionally, our model has been calibrated to be used with cells from patients with presumed
798 active TB. The exact same cells derived from an uninfected patient or a patient with latent TB
799 might behave differently, and the model would need to be recalibrated to different data. These
800 assumptions can be reassessed as we iterate this model to use it in answering new biological
801 questions.

802 While our model is able to represent a majority of the characteristics that could be
803 incorporated into a complex *in vitro* *Mtb* model, it still diverges from the idealized model in a
804 couple ways. No explicit environment impact on the cells in the simulation is included. It's known
805 that plastic and glass plates differ from *in vivo* environments, and as such extracellular matrix
806 (ECM) components like collagen have been incorporated into *in vitro* models. ECM can also
807 change the lifespan and movement of the cells and sequester chemokines. We plan to
808 incorporate ECM in future iterations. While primary human cells were represented, the bacteria
809 represented within this model is BCG, a model organism for *Mtb*, rather than *Mtb* itself. BCG
810 was used for preliminary analysis as it can be used outside of a BSL3 laboratory. Switching
811 between BCG and *Mtb* could be done by adjusting parameter values, but more detailed
812 pathways would need to be added if specific virulent strains were of interest.

813 **5. Conclusion**

814 In summary, we show a novel application of ABMs to *in vitro* TB infection culture
815 systems. In doing so, we introduce a framework to potentially integrate results from and
816 compare multiple *in vitro* models.

817

818 **Acknowledgements**

819 This work used the Extreme Science and Engineering Discovery Environment (XSEDE), which
820 is supported by National Science Foundation grant number ACI-1548562. Anvil at Purdue and
821 Expanse at UCSD were used through allocation TG-MDE220002. We also thank Lev
822 Gorenstein and the rest of the Research Computing Staff for their assistance with batch
823 computing at the Rosen Center for Advanced Computing. We would also like to acknowledge
824 Catherine Weathered for her mentorship and her work setting up the foundations in Repast and
825 Slurm for our lab.

826

827 **References**

- 828 1. World Health Organization. Global Tuberculosis Report [Internet]. 2022. Available from:
829 <https://www.ptonline.com/articles/how-to-get-better-mfi-results>
- 830 2. Stek C, Allwood B, Walker NF, Wilkinson RJ, Lynen L, Meintjes G. The Immune
831 Mechanisms of Lung Parenchymal Damage in Tuberculosis and the Role of Host-
832 Directed Therapy. *Front Microbiol* [Internet]. 2018 Oct 30 [cited 2021 Jun 30];9. Available
833 from: <https://pubmed.ncbi.nlm.nih.gov/30425706/>
- 834 3. Edagwa BJ, Guo D, Puligujja P, Chen H, McMillan JE, Liu X, et al. Long-acting
835 antituberculous therapeutic nanoparticles target macrophage endosomes. *FASEB J*
836 [Internet]. 2014 Dec 1 [cited 2021 Mar 28];28(12):5071–82. Available from:
837 [/pmc/articles/PMC4232285/](https://pmc/articles/PMC4232285/)
- 838 4. Sakamoto K, Kim MJ, Rhoades ER, Allavena RE, Ehrt S, Wainwright HC, et al.
839 Mycobacterial Trehalose Dimycolate Reprograms Macrophage Global Gene Expression

840 and Activates Matrix Metalloproteinases. McCormick BA, editor. *Infect Immun* [Internet].
841 2013 Mar [cited 2021 Aug 6];81(3):764–76. Available from:
842 <https://pubmed.ncbi.nlm.nih.gov/23264051/>

843 5. Mehra S, Pahar B, Dutta NK, Conerly CN, Philippi-Falkenstein K, Alvarez X, et al.
844 Transcriptional Reprogramming in Nonhuman Primate (Rhesus Macaque) Tuberculosis
845 Granulomas. Jeyaseelan S, editor. *PLoS One* [Internet]. 2010 Aug 31 [cited 2021 Aug
846 13];5(8):e12266. Available from: <https://pubmed.ncbi.nlm.nih.gov/20824205/>

847 6. Qualls JE, Murray PJ. Immunometabolism within the tuberculosis granuloma: amino
848 acids, hypoxia, and cellular respiration. *Semin Immunopathol* [Internet]. 2016 Mar 1 [cited
849 2021 Nov 29];38(2):139. Available from: [/pmc/articles/PMC4779414/](https://pmc/articles/PMC4779414/)

850 7. Pagán AJ, Ramakrishnan L. Immunity and immunopathology in the tuberculous
851 granuloma. *Cold Spring Harb Perspect Med* [Internet]. 2015 Sep 1 [cited 2021 Jul
852 30];5(9):1–20. Available from: <https://pubmed.ncbi.nlm.nih.gov/25377142/>

853 8. Flores-Valdez MA, Kupz A, Subbian S. Recent Developments in Mycobacteria-Based
854 Live Attenuated Vaccine Candidates for Tuberculosis. *Biomedicines* [Internet]. 2022 Nov
855 1 [cited 2023 Feb 9];10(11). Available from: [/pmc/articles/PMC9687462/](https://pmc/articles/PMC9687462/)

856 9. Dehnad A, Ravindran R, Subbian S, Khan IH. Development of immune-biomarkers of
857 pulmonary tuberculosis in a rabbit model. *Tuberculosis*. 2016 Dec 1;101:1–7.

858 10. Lin PL, Pawar S, Myers A, Pegu A, Fuhrman C, Reinhart TA, et al. Early events in
859 Mycobacterium tuberculosis infection in cynomolgus macaques. *Infect Immun* [Internet].
860 2006 Jul [cited 2020 Jun 29];74(7):3790–803. Available from:
861 <https://pubmed.ncbi.nlm.nih.gov/16790751/>

862 11. Lin PL, Flynn JL. The End of the Binary Era: Revisiting the Spectrum of Tuberculosis. *J
863 Immunol* [Internet]. 2018 Nov 1 [cited 2020 Jun 30];201(9):2541–8. Available from:
864 <https://pubmed.ncbi.nlm.nih.gov/30348659/>

865 12. Elkington P, Lerm M, Kapoor N, Mahon R, Pienaar E, Huh D, et al. In vitro granuloma

866 models of tuberculosis: Potential and challenges [Internet]. Vol. 219, Journal of Infectious
867 Diseases. Oxford University Press; 2019 [cited 2020 Aug 10]. p. 1858–66. Available from:
868 [/pmc/articles/PMC6534193/?report=abstract](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6534193/?report=abstract)

869 13. Kotze LA, Beltran CGG, Lang D, Loxton AG, Cooper S, Meiring M, et al. Establishment of
870 a Patient-Derived, Magnetic Levitation-Based, Three-Dimensional Spheroid Granuloma
871 Model for Human Tuberculosis. *mSphere* [Internet]. 2021 Aug 25 [cited 2021 Nov
872 16];6(4). Available from: [/pmc/articles/PMC8386456/](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8386456/)

873 14. Pitcher MJ, Dobson SA, Kelsey TW, Chaplain MAJ, Sloan DJ, Gillespie SH, et al. How
874 mechanistic in silico modelling can improve our understanding of TB disease and
875 treatment. *INT J TUBERC LUNG DIS* [Internet]. [cited 2021 Jul 2];24(11). Available from:
876 <http://dx.doi.org/10.5588/ijtld.20.0107>

877 15. Joslyn LR, Linderman JJ, Kirschner DE. A virtual host model of *Mycobacterium*
878 tuberculosis infection identifies early immune events as predictive of infection outcomes.
879 bioRxiv [Internet]. 2021 Nov 10 [cited 2021 Nov 16];2021.11.08.467840. Available from:
880 <https://www.biorxiv.org/content/10.1101/2021.11.08.467840v1>

881 16. Wessler T, Joslyn LR, Borish HJ, Gideon HP, Flynn JL, Kirschner DE, et al. A
882 computational model tracks whole-lung *Mycobacterium* tuberculosis infection and
883 predicts factors that inhibit dissemination. *PLoS Comput Biol* [Internet]. 2020 May 1 [cited
884 2021 Aug 25];16(5). Available from: [/pmc/articles/PMC7239387/](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7239387/)

885 17. Waaler H, Geser A, Andersen S. The Use of Mathematical Models in the Study of the
886 Epidemiology of Tuberculosis. *Am J Public Heal Nations Heal* [Internet]. 1962 Jun 1 [cited
887 2021 Aug 10];52(6):1002. Available from:
888 <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1523050/>

889 18. Kirschner D, Pienaar E, Marino S, Linderman JJ. A review of computational and
890 mathematical modeling contributions to our understanding of *Mycobacterium* tuberculosis
891 within-host infection and treatment. *Curr Opin Syst Biol* [Internet]. 2017 Jun 1 [cited 2020

892 Sep 10];3:170. Available from: /pmc/articles/PMC6354243/

893 19. Segovia-Juarez JL, Ganguli S, Kirschner D. Identifying control mechanisms of granuloma

894 formation during *M. tuberculosis* infection using an agent-based model. *J Theor Biol*

895 [Internet]. 2004 Dec 7 [cited 2021 Jun 9];231(3):357–76. Available from:

896 <https://pubmed.ncbi.nlm.nih.gov/15501468/>

897 20. Fallahi-Sichani M, El-Kebir M, Marino S, Kirschner DE, Linderman JJ. a. *J Immunol*

898 [Internet]. 2011 Mar 15 [cited 2020 Jul 15];186(6):3472–83. Available from:

899 <https://pubmed.ncbi.nlm.nih.gov/21321109/>

900 21. Fallahi-Sichani M, Schaller MA, Kirschner DE, Kunkel SL, Linderman JJ. Identification of

901 Key Processes that Control Tumor Necrosis Factor Availability in a Tuberculosis

902 Granuloma. *PLOS Comput Biol* [Internet]. 2010 May [cited 2021 Dec 5];6(5):e1000778.

903 Available from:

904 <https://journals.plos.org/ploscompbiol/article?id=10.1371/journal.pcbi.1000778>

905 22. Fallahi-Sichani M, Kirschner DE, Linderman JJ. NF-KB signaling dynamics play a key

906 role in infection control in tuberculosis. *Front Physiol* [Internet]. 2012 Jun 6 [cited 2020

907 Aug 30];3 JUN:170. Available from: www.frontiersin.org

908 23. Pienaar E, Matern WM, Linderman JJ, Bader JS, Kirschner DE. Multiscale model of

909 Mycobacterium tuberculosis infection maps metabolite and gene perturbations to

910 granuloma sterilization predictions. *Infect Immun* [Internet]. 2016 May 1 [cited 2020 Sep

911 8];84(5):1650–69. Available from: /pmc/articles/PMC4862722/?report=abstract

912 24. Marino S, Cilfone NA, Mattila JT, Linderman JJ, Flynn JL, Kirschner DE. Macrophage

913 polarization drives granuloma outcome during *Mycobacterium tuberculosis* infection.

914 *Infect Immun* [Internet]. 2015 Jan 1 [cited 2021 May 25];83(1):324–38. Available from:

915 <http://dx.doi.org/10.1128>

916 25. Sershen CL, Plimpton SJ, May EE. Oxygen modulates the effectiveness of granuloma

917 mediated host response to *Mycobacterium tuberculosis*: A multiscale computational

biology approach. *Front Cell Infect Microbiol.* 2016;6(FEB):1–25.

26. Warsinske HC, Pienaar E, Linderman JJ, Mattila JT, Kirschner DE. Deletion of TGF- β 1 increases bacterial clearance by cytotoxic t cells in a tuberculosis granuloma model. *Front Immunol.* 2017 Dec 20;8(DEC):1843.

27. Pienaar E, Dartois V, Linderman JJ, Kirschner DE. In silico evaluation and exploration of antibiotic tuberculosis treatment regimens. *BMC Syst Biol* [Internet]. 2015 Dec 14 [cited 2021 Jul 14];9(1):79. Available from: <https://pubmed.ncbi.nlm.nih.gov/26578235/>

28. Cilfone NA, Ford CB, Marino S, Mattila JT, Gideon HP, Flynn JL, et al. Computational modeling predicts IL-10 control of lesion sterilization by balancing early host immunity-mediated antimicrobial responses with caseation during mycobacterium tuberculosis infection. *J Immunol* [Internet]. 2015 Jan 15 [cited 2021 Dec 6];194(2):664–77. Available from: <https://pubmed.ncbi.nlm.nih.gov/25512604/>

29. Cilfone NA, Perry CR, Kirschner DE, Linderman JJ. Multi-Scale Modeling Predicts a Balance of Tumor Necrosis Factor- α and Interleukin-10 Controls the Granuloma Environment during Mycobacterium tuberculosis Infection. *PLoS One* [Internet]. 2013 Jul 15 [cited 2021 Dec 5];8(7). Available from: [/pmc/articles/PMC3711807/](https://pmc/articles/PMC3711807/)

30. Warrender C, Forrest S, Koster F. Modeling intercellular interactions in early Mycobacterium infection. *Bull Math Biol* [Internet]. 2006 Nov [cited 2021 Dec 5];68(8):2233–61. Available from: <https://pubmed.ncbi.nlm.nih.gov/17086496/>

31. Nahid P, Dorman SE, Alipanah N, Barry PM, Brozek JL, Cattamanchi A, et al. Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America Clinical Practice Guidelines: Treatment of Drug-Susceptible Tuberculosis [Internet]. Vol. 63, *Clinical Infectious Diseases*. Oxford University Press; 2016 [cited 2021 Apr 7]. p. e147–95. Available from: <https://academic.oup.com/cid/article/63/7/e147/2196792>

32. Krombach F, Münzing S, Allmeling AM, Gerlach JT, Behr J, Dörger M. Cell size of

944 alveolar macrophages: an interspecies comparison. *Environ Health Perspect.* 1997;105
945 Suppl 5:1261–3.

946 33. Barros-Becker F, Lam PY, Fisher R, Huttenlocher A. Live imaging reveals distinct modes
947 of neutrophil and macrophage migration within interstitial tissues. *J Cell Sci* [Internet].
948 2017 Nov 11 [cited 2022 Nov 3];130(22):3801–8. Available from:
949 [/pmc/articles/PMC5702045/](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5702045/)

950 34. Pixley FJ. Macrophage migration and its regulation by CSF-1. *Int J Cell Biol.* 2012;
951 35. Bzymek R, Horsthemke M, Isfort K, Mohr S, Tjaden K, Müller-Tidow C, et al. Real-time
952 two- and three-dimensional imaging of monocyte motility and navigation on planar
953 surfaces and in collagen matrices: roles of Rho. *Sci Reports* 2016 61 [Internet]. 2016 Apr
954 28 [cited 2022 Nov 3];6(1):1–15. Available from:
955 <https://www.nature.com/articles/srep25016>

956 36. Grabher C, Cliffe A, Miura K, Hayflick J, Pepperkok R, Rørth P, et al. Birth and life of
957 tissue macrophages and their migration in embryogenesis and inflammation in medaka. *J*
958 *Leukoc Biol* [Internet]. 2007 Jan 1 [cited 2022 Nov 3];81(1):263–71. Available from:
959 <https://onlinelibrary.wiley.com/doi/full/10.1189/jlb.0806526>

960 37. Weathered C, Pennington K, Escalante P, Pienaar E. The Role of Biofilms, Bacterial
961 Phenotypes, and Innate Immune Response in *Mycobacterium avium* Colonization to
962 Infection. *J Theor Biol* [Internet]. 2022;534:110949. Available from:
963 <https://doi.org/10.1016/j.jtbi.2021.110949>

964 38. Cilfone NA, Kirschner DE, Linderman JJ. Strategies for Efficient Numerical
965 Implementation of Hybrid Multi-scale Agent-Based Models to Describe Biological
966 Systems. *Cell Mol Bioeng* [Internet]. 2015 Mar 1 [cited 2022 Jul 5];8(1):119–36. Available
967 from: <https://link.springer.com/article/10.1007/s12195-014-0363-6>

968 39. Martinez FO, Gordon S. The M1 and M2 paradigm of macrophage activation: Time for
969 reassessment. *F1000Prime Rep* [Internet]. 2014 Mar 3 [cited 2021 Jun 8];6. Available

970 from: /pmc/articles/PMC3944738/

971 40. Murphy K, Weaver C, Janeway C, Murphy Weaver, Casey,, Janeway, Charles,, K.
972 Janeway's immunobiology. 2017.

973 41. Repasy T, Lee J, Marino S, Martinez N, Kirschner DE, Hendricks G, et al. Intracellular
974 Bacillary Burden Reflects a Burst Size for Mycobacterium tuberculosis In Vivo. PLoS
975 Pathog [Internet]. 2013 Feb [cited 2021 May 24];9(2). Available from:
976 <https://pubmed.ncbi.nlm.nih.gov/23436998/>

977 42. Xue Q, Lu Y, Eisele MR, Sulistijo ES, Khan N, Fan R, et al. Analysis of single-cell
978 cytokine secretion reveals a role for paracrine signaling in coordinating macrophage
979 responses to TLR4 stimulation. Sci Signal. 2015;8(381):ra59.

980 43. Bevan MJ. Helping the CD8+ T-cell response [Internet]. Nature Reviews Immunology
981 Nature Publishing Group; 2004 p. 595–602. Available from:
982 www.nature.com/reviews/immunol

983 44. Aldridge BB, Fernandez-Suarez M, Heller D, Ambravaneswaran V, Irimia D, Toner M, et
984 al. Asymmetry and aging of mycobacterial cells leads to variable growth and antibiotic
985 susceptibility. Science [Internet]. 2012 Jan 1 [cited 2022 Dec 1];335(6064):100. Available
986 from: /pmc/articles/PMC3397429/

987 45. Abedon ST, Bartom E. Multiplicity of Infection [Internet]. Vol. 4, Brenner's Encyclopedia of
988 Genetics: Second Edition. Elsevier Inc.; 2013. 509–510 p. Available from:
989 <http://dx.doi.org/10.1016/B978-0-12-374984-0.00989-X>

990 46. Kokuina E, Breff-Fonseca MC, Villegas-Valverde CA, Mora-Díaz I. Normal Values of T, B
991 and NK Lymphocyte Subpopulations in Peripheral Blood of Healthy Cuban Adults
992 [Internet]. Vol. 21, MEDICC Review. [cited 2021 Apr 1]. Available from:
993 www.mediccreview.org/gate-strategy

994 47. Wallace DL, Zhang Y, Ghattas H, Worth A, Irvine A, Bennett AR, et al. Direct
995 Measurement of T Cell Subset Kinetics In Vivo in Elderly Men and Women. J Immunol.

996 2004 Aug 1;173(3):1787–94.

997 48. Kwok WW, Tan V, Gillette L, Littell CT, Soltis MA, LaFond RB, et al. Frequency of
998 Epitope-Specific Naive CD4 + T Cells Correlates with Immunodominance in the Human
999 Memory Repertoire . *J Immunol* [Internet]. 2012 Mar 15 [cited 2021 May 24];188(6):2537–
1000 44. Available from: /pmc/articles/PMC3997369/

1001 49. Patankar YR, Sutiwisesak R, Boyce S, Lai R, Lindestam Arlehamn CS, Sette A, et al.
1002 Limited recognition of *Mycobacterium tuberculosis*-infected macrophages by polyclonal
1003 CD4 and CD8 T cells from the lungs of infected mice. *Mucosal Immunol* [Internet]. 2020
1004 Jan 1 [cited 2021 Jun 9];13(1):140–8. Available from: <https://doi.org/10.1038/s41385-019-0217-6>

1005 50. North MJ, Collier NT, Ozik J, Tatara ER, Macal CM, Bragen M, et al. Complex adaptive
1006 systems modeling with Repast Simphony. *Complex Adapt Syst Model* [Internet]. 2013
1007 Dec 1 [cited 2021 Nov 18];1(1). Available from:
1008 <https://link.springer.com/articles/10.1186/2194-3206-1-3>

1009 51. Towns J, Cockerill T, Dahan M, Foster I, Gaither K, Grimshaw A, et al. XSEDE:
1010 Accelerating scientific discovery. *Comput Sci Eng*. 2014 Sep 1;16(5):62–74.

1011 52. Renardy M, Hult C, Evans S, Linderman JJ, Kirschner DE. Global sensitivity analysis of
1012 biological multiscale models. *Curr Opin Biomed Eng* [Internet]. 2019;11:109–16. Available
1013 from: <https://doi.org/10.1016/j.cobme.2019.09.012>

1014 53. Beste DJV, Espasa M, Bonde B, Kierzek AM, Stewart GR, McFadden J. The genetic
1015 requirements for fast and slow growth in mycobacteria. *PLoS One*. 2009 Apr 28;4(4).

1016 54. Linderman JJ, Riggs T, Pande M, Miller M, Marino S, Kirschner DE. Characterizing the
1017 Dynamics of CD4+ T Cell Priming within a Lymph Node. *J Immunol* [Internet]. 2010 Mar
1018 15 [cited 2020 Mar 11];184(6):2873–85. Available from:
1019 <http://www.jimmunol.org/lookup/doi/10.4049/jimmunol.0903117>

1020 55. De Boer RJ, Homann D, Perelson AS. Different Dynamics of CD4 + and CD8 + T Cell

1022 Responses During and After Acute Lymphocytic Choriomeningitis Virus Infection . J
1023 Immunol. 2003;171(8):3928–35.

1024 56. Foulds KE, Zenewicz LA, Shedlock DJ, Jiang J, Troy AE, Shen H. Cutting Edge: CD4
1025 and CD8 T Cells Are Intrinsically Different in Their Proliferative Responses. J Immunol
1026 [Internet]. 2002 Feb 15 [cited 2021 May 13];168(4):1528–32. Available from:
1027 <http://www.jimmunol.org/content/168/4/1528>.f
1028 ull#ref-list-1

1029 57. Obst R. The timing of T cell priming and cycling. Front Immunol. 2015;6(NOV):1–10.

1030 58. Baliu-Piqué M, Verheij MW, Drylewicz J, Ravesloot L, de Boer RJ, Koets A, et al. Short
1031 lifespans of memory T-cells in bone marrow, blood, and lymph nodes suggest that T-cell
1032 memory is maintained by continuous self-renewal of recirculating cells. Front Immunol
1033 [Internet]. 2018 Sep 11 [cited 2021 May 13];9(SEP):2054. Available from:
1034 www.frontiersin.org

1035 59. Parretta E, Cassese G, Santoni A, Guardiola J, Vecchio A, Di Rosa F. Kinetics of In Vivo
1036 Proliferation and Death of Memory and Naive CD8 T Cells: Parameter Estimation Based
1037 on 5-Bromo-2'-Deoxyuridine Incorporation in Spleen, Lymph Nodes, and Bone Marrow. J
1038 Immunol [Internet]. 2008 Jun 1 [cited 2021 May 13];180(11):7230–9. Available from:
1039 <http://www.jimmunol.org/content/180/11/7230>

1040 60. Borghans JAM, Tesselaar K, de Boer RJ. Current best estimates for the average
1041 lifespans of mouse and human leukocytes: reviewing two decades of deuterium-labeling
1042 experiments. Immunol Rev [Internet]. 2018 Sep 1 [cited 2022 Mar 11];285(1):233–48.
1043 Available from: <https://onlinelibrary.wiley.com/doi/full/10.1111/imr.12693>

1044 61. Wong P, Pamer EG. Cutting Edge: Antigen-Independent CD8 T Cell Proliferation. J
1045 Immunol [Internet]. 2001 May 15 [cited 2021 May 13];166(10):5864–8. Available from:
1046 <http://www.jimmunol.org/content/166/10/5864>.f
1047 4.full#ref-list-1

1048 62. Grant MR, Mostov KE, Tlsty TD, Hunt CA. Simulating Properties of In Vitro Epithelial Cell
1049 Morphogenesis. *PLOS Comput Biol* [Internet]. 2006 [cited 2022 Oct 27];2(10):e129.
1050 Available from:
1051 <https://journals.plos.org/ploscompbiol/article?id=10.1371/journal.pcbi.0020129>

1052 63. Berg DR, Offord CP, Kemler I, Ennis MK, Chang L, Paulik G, et al. In vitro and in silico
1053 multidimensional modeling of oncolytic tumor virotherapy dynamics. *PLoS Comput Biol*
1054 [Internet]. 2019 Mar 1 [cited 2022 Nov 3];15(3). Available from:
1055 [/pmc/articles/PMC6400333/](https://pmc/articles/PMC6400333/)

1056 64. Bednarczyk E, Lu Y, Paini A, Leite SB, Van Grunsven LA, Worth A, et al. Extension of the
1057 Virtual Cell Based Assay from a 2-D to a 3-D Cell Culture Model. 2019 [cited 2022 Nov
1058 3];50(1):45–56. Available from: <http://www>.

1059 65. Sego TJ, Kasacheuski U, Hauersperger D, Tovar A, Moldovan NI. A heuristic
1060 computational model of basic cellular processes and oxygenation during spheroid-
1061 dependent biofabrication. *Biofabrication*. 2017;9(2).

1062 66. Marino S, Hult C, Wolberg P, Linderman JJ, Kirschner DE. The role of dimensionality in
1063 understanding granuloma formation. *Computation* [Internet]. 2018 Dec 1 [cited 2020 Jul
1064 27];6(4). Available from: [/pmc/articles/PMC6599587/?report=abstract](https://pmc/articles/PMC6599587/?report=abstract)

1065 67. Wadee R, Wadee AA. The Pathology of Lymphocytes, Histiocytes, and Immune
1066 Mechanisms in *Mycobacterium tuberculosis* Granulomas. *Am J Trop Med Hyg* [Internet].
1067 2021 May 5 [cited 2022 Nov 7];104(5):1796. Available from: [/pmc/articles/PMC8103466/](https://pmc/articles/PMC8103466/)

1068 68. Marakalala MJ, Raju RM, Sharma K, Zhang YJ, Eugenin EA, Prideaux B, et al.
1069 Inflammatory signaling in human Tuberculosis granulomas is spatially organized. *Nat
1070 Med* [Internet]. 2016 May 1 [cited 2022 Aug 11];22(5):531. Available from:
1071 [/pmc/articles/PMC4860068/](https://pmc/articles/PMC4860068/)

1072 69. Mattila JT, Ojo OO, Kepka-Lenhart D, Marino S, Kim JH, Eum SY, et al.
1073 Microenvironments in Tuberculous Granulomas Are Delineated by Distinct Populations of

1074 Macrophage Subsets and Expression of Nitric Oxide Synthase and Arginase Isoforms. *J*
1075 *Immunol* [Internet]. 2013 Jul 15 [cited 2022 Nov 7];191(2):773–84. Available from:
1076 <https://www.jimmunol.org/content/191/2/773>

1077 70. Gideon HP, Phuah JY, Myers AJ, Bryson BD, Rodgers MA, Coleman MT, et al. Variability
1078 in Tuberculosis Granuloma T Cell Responses Exists, but a Balance of Pro- and Anti-
1079 inflammatory Cytokines Is Associated with Sterilization. *PLoS Pathog* [Internet]. 2015
1080 [cited 2022 Oct 21];11(1):1–28. Available from: [/pmc/articles/PMC4303275/](https://pmc/articles/PMC4303275/)

1081 71. Lenaerts A, Barry CE, Dartois V. Heterogeneity in tuberculosis pathology ,
1082 microenvironments and therapeutic responses. *Immunol Rev*. 2015;264:288–307.

1083 72. Evans S, Butler JR, Mattila JT, Kirschner DE. Systems biology predicts that fibrosis in
1084 tuberculous granulomas may arise through macrophage-to-myofibroblast transformation.
1085 Nie Q, editor. *PLOS Comput Biol* [Internet]. 2020 Dec 28 [cited 2021 Jun
1086 17];16(12):e1008520. Available from: <https://doi.org/10.1371/journal.pcbi.1008520.g001>

1087 73. Millar JA, Butler JR, Evans S, Mattila JT, Linderman JJ, Flynn JL, et al. Spatial
1088 Organization and Recruitment of Non-Specific T Cells May Limit T Cell-Macrophage
1089 Interactions Within *Mycobacterium tuberculosis* Granulomas. *Front Immunol*. 2021 Jan
1090 20;0:3496.

1091 74. Martinez V, Castilla-Lievre MA, Guillet-Caruba C, Grenier G, Fior R, Desarnaud S, et al.
1092 18F-FDG PET/CT in tuberculosis: an early non-invasive marker of therapeutic response.
1093 *Int J Tuberc Lung Dis*. 2012 Sep 1;16(9):1180–5.

1094 75. Yu WY, Lu PX, Assadi M, Huang XL, Skrahan A, Rosenthal A, et al. Updates on 18F-
1095 FDG-PET/CT as a clinical tool for tuberculosis evaluation and therapeutic monitoring.
1096 *Quant Imaging Med Surg* [Internet]. 2019 [cited 2020 Jul 22];9(6). Available from:
1097 <https://pubmed.ncbi.nlm.nih.gov/31367568/>

1098 76. Lin PL, Ford CB, Coleman MT, Myers AJ, Gawande R, Ioerger T, et al. Sterilization of
1099 granulomas is common in active and latent tuberculosis despite within-host variability in

1100 bacterial killing. *Nat Med* [Internet]. 2014 [cited 2021 May 25];20(1):75–9. Available from:
1101 <https://pubmed.ncbi.nlm.nih.gov/24336248/>

1102 77. Davis JM, Ramakrishnan L. The Role of the Granuloma in Expansion and Dissemination
1103 of Early Tuberculous Infection. *Cell* [Internet]. 2009 Jan 9 [cited 2021 Aug 13];136(1):37–
1104 49. Available from: <https://pubmed.ncbi.nlm.nih.gov/19135887/>

1105 78. Cronan MR, Matty MA, Rosenberg AF, Blanc L, Pyle CJ, Espenschied ST, et al. An
1106 Explant Technique for High-Resolution Imaging and Manipulation of Mycobacterial
1107 Granulomas. *Nat Methods* [Internet]. 2018 [cited 2022 Dec 16];15(12):1098–107.
1108 Available from: http://www.nature.com/authors/editorial_policies/license.html#terms

1109 79. Cadena AM, Fortune SM, Flynn JL. Heterogeneity in tuberculosis. *Nat Rev Immunol*
1110 [Internet]. 2017 Oct 27 [cited 2022 Nov 7];17(11):691. Available from:
1111 [/pmc/articles/PMC6247113/](https://pmc/articles/PMC6247113/)

1112 80. Lin PL, Rodgers M, Smith L, Bigbee M, Myers A, Bigbee C, et al. Quantitative
1113 comparison of active and latent tuberculosis in the cynomolgus macaque model. *Infect*
1114 *Immun*. 2009;77(10):4631–42.

1115 81. Hunter L, Hingley-Wilson S, Stewart GR, Sharpe SA, Salguero FJ. Dynamics of
1116 Macrophage, T and B Cell Infiltration Within Pulmonary Granulomas Induced by
1117 Mycobacterium tuberculosis in Two Non-Human Primate Models of Aerosol Infection.
1118 *Front Immunol* [Internet]. 2022 Jan 6 [cited 2022 Nov 8];12:1. Available from:
1119 [/pmc/articles/PMC8770544/](https://pmc/articles/PMC8770544/)

1120

1121 **Supplementary Information Captions**

1122 **Table 1:** Parameters that were held constant during sampling, their values, and units.
1123 **Figure 1:** Distribution of parameters in calibrated runs. The ranges of the parameters have been
1124 normalized from 0 to 1 with the bounds representing the minimum and maximum of the ranges
1125 listed in *Table 1*.